论文部分内容阅读
目的系统评价厄洛替尼联合吉西他滨治疗胰腺癌的有效性和安全性。方法计算机检索Medline、EMbase、Cochrane Library、Clinical Trials、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普和万方数据库,收集厄洛替尼联合吉西他滨治疗胰腺癌的临床研究,并进行文献质量评价和资料提取,用Rev Man 5.3软件进行Meta分析。结果共纳入5项研究,共计935例患者。Meta分析结果显示,和对照组相比,试验组不能提高胰腺癌治疗的有效率和控制率(均P>0.05),但能提高患者一年生存率(P<0.05),延长无病生存期(P<0.001)和总生存期(P<0.001)。试验组皮疹(P<0.01)和腹泻(P<0.05)的发生率均高于对照组。结论厄洛替尼联合吉西他滨对延长胰腺癌患者生存期有优势,但有一定的不良反应,应充分考虑患者的实际情况进行个体化治疗。
Objective To systematically evaluate the efficacy and safety of erlotinib combined with gemcitabine in the treatment of pancreatic cancer. METHODS: Computer research was conducted on Medline, EMbase, Cochrane Library, Clinical Trials, China Biomedical Literature Database (CBM), China Knowledge Network (CNKI), Weipu, and Wanfang Database to collect clinical studies of erlotinib combined with gemcitabine in the treatment of pancreatic cancer. Document quality evaluation and data extraction were performed and Meta analysis was performed using Rev Man 5.3 software. Results A total of 5 studies were included with a total of 935 patients. Meta-analysis showed that compared with the control group, the experimental group could not improve the efficiency and control rate of pancreatic cancer treatment (all P>0.05), but it could increase the one-year survival rate (P<0.05) and prolong the disease-free survival. (P<0.001) and overall survival (P<0.001). The incidence of rash (P<0.01) and diarrhea (P<0.05) in the experimental group was higher than that in the control group. Conclusion Erlotinib combined with gemcitabine has advantages in prolonging the survival period of patients with pancreatic cancer, but there are certain adverse reactions. Individualized treatment should be fully considered in the actual situation of patients.